NEW YORK—Eyenovia, Inc. (NASDAQ: EYEN), a commercial-stage company that develops topical ophthalmic therapies, has announced the closing of its public offering of 12,850,000 shares of common stock at a price per share of $0.40. The gross proceeds to Eyenovia from this offering are approximately $5.14 million before deducting the placement agent’s fees and other offering expenses payable by Eyenovia, the announcement said. The company said it intends to use the net proceeds from this offering to fund commercialization activities for Mydcombi (an FDA-approved fixed dose combination ophthalmic spray for pupil dilation) and clobetasol propionate (an FDA-approved steroid for the treatment of post-operative inflammation and pain following ocular surgery), and complete the Chaperone pediatric myopia clinical study.

The company also intends to use the net proceeds for working capital and general corporate purposes, which may include the repayment of a portion of existing indebtedness.

According to Eyenovia, Dawson James Securities, Inc. acted as the placement agent for this offering.